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Platelet Production After Administration of
Antiplatelet Serum and 5-Fluorouracil
By J. M. Radley, G. S. Hodgson, and J. Levin
Although 5-fluorouracil induces relatively minimal thrombocytopenia in mice compared with antiplatelet serum, the
ensuing rebound thrombocytosis is much greater. It also occurs several days later. Administration of 5-fluorouracil 24 hr
after antiplatelet serum suppresses the increase in platelets produced by antiplatelet serum, while the subsequent
thrombocytosis is indistinguishable from that produced by 5-flourouracil alone. It is concluded that the thrombocytosis
that occurs after 5-flourouracil originates from a class of primitive stem cells, or early megakaryocyte precursors, which
are not killed by the drug. Thrombocytosis occurring after antiplatelet serum is derived from more mature precursor cells,
which are sensitive to 5-fluorouracil.
T HERE is considerable evidence that the pro-
duction of platelets by megakaryocytes normally
reflects the level or mass of circulating platelets.’
Thus, thrombocytosis produced by hypertransfusion of
platelets is followed by rebound thrombocytopenia,2
while thrombocytopenia induced by exchange transfu-
sion or the administration of antiplatelet serum is
followed by an increased production of plate-
lets.3tChanges in the replicative activity of megaka-
ryocytes are undetectable until I 8-25 hr after applica-
tion of the stimulus.36 This time lag is thought to
represent either a delay in the production of humoral
substance (thrombopoietin) responsible for altered
thrombopoiesis, or the necessary changes that must
occur in unrecognizable megakaryocyte precursor
cells, or both.7’8
Recently, it has been found that mice recovering
from the cytotoxic effects of 5-fluorouracil ( I 50
mg/kg body weight) exhibit a marked increase in
megakaryocytopoiesis in bone marrow.9 The appear-
ance of increased numbers of megakaryocytes is
followed by a high level of platelets in the peripheral
blood I I days after 5-fluorouracil.’#{176} The degree of
rebound thrombocytosis exceeds that reported after
antiplatelet serum,S although the latter produces a
much greater depression in the circulating platelet
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level. This suggests a more complex system of control
of platelet levels than considered hitherto.
The dose of 5-fluorouracil used in the above experi-
ments kills proliferating hemopoietic cells for up to 2
days.#{176}”2 If, normally, either stem cells or committed
megakaryocyte precursors remain out of cycle for long
periods, they might escape the lethal effects of 5-
fluorouracil and thus be responsible for the enhanced
megakaryocytopoiesis. We sought to distinguish which
of these two cell types is responsible by using anti-
platelet serum to promote replicative activity among
committed megakaryocyte precursors and then
administering 5-fluorouracil 24 hr later.
MATERIALS AND METHODS
Female mice of the CS7BL/6J strain, aged about 18 wk, were
used for the experiments. Fifty mice were injected intravenously, via
the tail vein, with 50 ￿zl antiplatelet serum and were then divided
into 2 groups: one, comprising 28 mice, received no further injection;
the other was injected intravenously with 5-fluorouracil ( I 50 mg/kg
body weight) 24 hr later. A third group of 22 mice was injected with
5-fluorouracil at the same time. A fourth group comprised unin-
jected controls. At times (Fig. I). mice were bled for platelet counts,
each mouse being used once only. Control mice also were bled at
each time point.
Antiplatelet serum was obtained from rabbits that had been
immunized by multiple serial subcutaneous and intramuscular
injections of washed frozen-thawed platelets, suspended in Freund’s
adjuvant, from C57BL/6J mice. Preliminary experiments indicated
that 0.05 ml ofantiplatelet serum was the lowest dose that produced
reproducible, severe, acute thrombocytopenia (platelet counts
approximately 5% of normal).
Platelet counts were carried out using phase microscopy on 20 ￿l
blood sampled from the retroorbital plexus and diluted 1:50 in 1%
ammonium oxalate.
RESULTS AND DISCUSSION
Thirty minutes after the administration of anti-
platelet serum, the circulating platelet count was
reduced to 7% of normal (Fig. 1). Rapid recovery
occurred between days 2 and 5, when a maximum
plateau was reached at I .6 times normal. The platelet
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Fig. 1 . Mean peripheral blood platelet counts ( ± SEM) after
antiplatelet serum, 5-fluorouracil, and antiplatelet serum plus
5-fluorouracil (4 mice per point except day 15 when there were 2;
controls are the mean of 1 6 mice). Times of injection of anti-
platelet serum (APS) and 5-fluorouracil (5FU) are shown.
count returned to normal by day I 2. This response is
similar to those reported by others.3’5
Five-fluorouracil given 24 hr after the antiplatelet
serum effectively prevented the rise in platelet counts
seen with the antiplatelet serum alone, a result consist-
ent with 5-fluorouracil killing megakaryocyte precur-
sors that had been stimulated to proliferate by anti-
platelet serum. The small elevation in the platelet
count seen 4 days after 5-fluorouracil can be acounted
for by platelet release from maturing megakaryocytes,
which are beyond their replication phase at the time of
5-fluorouracil injection. The subsequent fall and rise
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in the platelet count was indistinguishable from that
after 5-fluorouracil alone.
We have concluded that the later and more marked
thrombocytosis, which begins about 9 days after 5-
fluorouracil, does not originate from megakaryocyte
5 -Fluorouracil precursors normally present in the bone marrow and
responsive to thrombocytopenia induced by anti-
platelet serum. Rather, it would appear to originate
from proliferation of a class of “primitive” (pre-CFU-
513) stem cells in the bone marrow that survive 5-
fluorouracil and are efficient at regenerating the
megakaryocyte population of a lethally irradiated
host.’4 The possibility also exists that the increased
thrombopoiesis may derive from early committed
megakaryocyte precursor cells with high proliferative
potential that are generally noncycling, if this type of
cell is present in the megakaryocyte pathway of differ-
entiation. There is evidence for such a cell in the
granulocytic-macrophage series.’5 It remains to be
established whether or not the megakaryocyte proge-
nitors that can be grown in vitro (CFU-M 6) are
involved in the post-5-fluorouracil rebound thrombo-
cytosis.
Once the cell type responsible is stimulated to
proliferate and produce megakaryocytes, the normal
mechanisms controlling platelet production appear to
be relatively ineffectual, and a marked rebound
thrombocytosis occurs. Further study of the effects of
5-fluorouracil on mouse bone marrow may help to
extend knowledge concerning stem cell commitment
and the control of megakaryocyte precursors.
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